SOURCE: Barrier Therapeutics, Inc.

May 03, 2006 13:00 ET

Barrier Therapeutics to Present at Morgan Stanley Global Healthcare Unplugged Conference

PRINCETON, NJ -- (MARKET WIRE) -- May 3, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer, is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference.

The conference will be held at the Mandarin Oriental in Miami, Florida on May 3-5, 2006. Dr. Cauwenbergh is scheduled to present on Friday, May 5th, at 11:00 a.m. Eastern Time.

The presentation will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0% and tretinoin 0.01%) Topical Solution. The Company also markets its Solagé® product in Canada, along with VANIQA® (elflornithine HCI) Cream 13.9%, for which it is the exclusive distributor in Canada. Barrier's Sebazole™ (2% ketoconazole) product candidate, for the treatment of seborrheic dermatitis, is currently under FDA review. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site:

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Jane Petrino